Date | Inventory | Goodwill | Total Assets | Current Liabilities |
---|
CEO | Mr. Juan Jose Gonzalez |
IPO Date | April 28, 2021 |
Location | Switzerland |
Headquarters | Dammstrasse 19 |
Employees | 1,277 |
Sector | Healthcare |
Industries |
PolyPeptide Group AG operate as a contract development and manufacturing company worldwide. It focuses on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development, and in generic products. It engages in manufacturing custom research grade peptides; and developing neoantigen peptide to support personalized cancer therapies. The company is also involved in manufacturing peptides for commercially approved peptide therapeutics. In addition, it manufactures peptide-based generics for human and veterinary markets; and cosmetic peptides. Further, the company offers regulatory affair support services. The company was founded in 1952 and is headquartered in Zug, Switzerland. PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V.
Past 5 years
USD 377.87
USD 291.69
USD 63.22
USD 1.17 K
StockViz Staff
February 6, 2025
Any question? Send us an email